Lonza has expanded its service offering for orally delivered biologic therapies to support the development and manufacturing needs of smart capsules companies.
 
Delivering biologics through an oral administration route is a growing market. Since most new drug entities face bioavailability challenges, exploring new delivery solutions to mitigate these challenges is of great value to drug developers and their patients.
 
Lonza aims to explore the potential of oral biologics with smart capsules, designed to enhance precision, efficacy, and control by using electronic or mechanical elements to deliver drugs to the stomach or intestine. They have promising applications in areas such as diabetes, obesity, and other therapeutic fields. Lonza has expanded its offering for orally delivered biologics with tailored development and manufacturing services focusing on the specific needs of smart capsules companies.
 
The offering leverages Lonza’s customized capsule services tailored to specific requirements, including size, design, and lock mechanisms. It also offers a variety of functionalities, such as targeted release using a bi-layer manufacturing technology, adjustable to the needs of the respective API.
 
Bart Pelgrims, Vice President, R&D, Capsules & Health Ingredients, Lonza, said, “The strong market interest in this bespoke offering for smart capsules, marked by the first customer already on board and additional discussions in progress, reinforces the value of our approach. By ensuring every detail of development, which goes beyond formulation, we are confident in our ability to support smart capsule innovators to help shape the future of healthcare.”